Víctor Jiménez‐Yuste

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel et al. · New England Journal of Medicine · 2018 · 745 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Steven W. Pipe, Midori Shima, Michaela Lehle et al. · The Lancet Haematology · 2019 · 385 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +5

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Guy Young, Ri Liesner, Tiffany Chang et al. · Blood · 2019 · 384 citations · Full text

Medicine, Hematology, Pharmacology +6

International recommendations on the diagnosis and treatment of acquired hemophilia A

Andreas Tiede, Peter W. Collins, Paul Knoebl et al. · Haematologica · 2020 · 373 citations · Full text

Medicine, Hematology, Immunology +17

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel et al. · Blood · 2020 · 289 citations · Full text

Medicine, Hematology, Pharmacotherapy +16